China's mRNA vaccine firm Abogen raises over US$700m from investors including Temasek
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[BEIJING] China's Suzhou Abogen Biosciences said on Thursday it has raised over US$700 million to support clinical development of its potential Covid-19 vaccine and expand pipeline of other vaccine and treatment candidates.
Abogen's potential shot against the new coronavirus, which it is jointly developing with a research institute affiliated with Chinese military and Walvax Biotechnology, adopts the messenger RNA (mRNA) technology.
The candidate ARCoV is being tested in a Phase III clinical trial.
The fundraising was led by seven investors, including Singapore's state investment firm Temasek Holdings and Hillhouse-backed GL ventures, Abogen said in a statement.
REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Ministry of Home Affairs Permanent Secretary Pang Kin Keong to retire
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
